Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance

Amylx Pharmaceuticals IncTrade
iShares Broad USD Investment Grade Corporate BondTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.21. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.

AMLXUSIG
Market Cap
$2.64B
Sector
HealthFixed Income
52-Week High
$24.19$52.69
52-Week Low
$7.82$50.18
Enterprise Value
$2.39B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About iShares Broad USD Investment Grade Corporate Bond

USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.

Read more on USIG